------------------------------------------------------------
[link removed]


** Understanding the AMP Results and So Much More
------------------------------------------------------------
July 8, 2021

Dear Advocate,

We’re delighted to share our new publication Understanding Results of the AMP Trials ([link removed]) . The first results of these landmark trials were announced in early 2021, but their implications will be echoing for years to come. This guide provides a foundation for advocates.

The AMP trials ([link removed]) evaluated the ability of a broadly neutralizing antibody (bNAb), called VRC01, to protect against HIV. The trials showed that VRC01 did not reduce the overall risk of acquiring HIV. However, VRC01 protected some individuals from infection by HIV viruses that were particularly vulnerable or “sensitive” to the antibody. Together these results mean AMP will inform future bNAb and vaccine studies. Read Understanding Results ([link removed]) to learn more; listen to our Px Pulse podcast to dive into the AMP trials; ([link removed]) and check out AVACer Daisy Ouya’s commentary on the AMP trials ([link removed]) in the latest issue of IAVI’s ([link removed]) Voices: Community Perspectives on Clinical Research
([link removed]) .

Also, in case you missed it, we’re highlighting a few other important resources to inform prevention advocacy:
* More on Antibodies: IAVI ([link removed]) and Wellcome ([link removed]) recorded this webinar, Enhancing regulatory and policy frameworks for monoclonal antibodies (mAbs) in Africa: lessons learned from vaccines ([link removed]) .
* All Things PrEP: The PrEP Learning Network ([link removed]) hosted a webinar, Reframing PrEP Continuation: Highlights from the PMM-Jhpiego-USAID Think Tank on Prevention Effective Use Of PrEP ([link removed]) .
* Put a Ring on It: The latest issue of the quarterly PROMISE-CHOICE Dapivirine Ring Newsletter ([link removed]) features updates on advances of the Dapivirine Vaginal Ring. Find news from researchers, civil society, country implementers and invitations for workshops and other events.
* PEPFAR Needs a Leader: Devex ([link removed]) recently published a commentary, US leadership matters in fighting AIDS ([link removed]) , co-authored by AVAC’s Mitchell Warren and Emory University’s Carlos del Rio on the imperative for US President Joe Biden to end the delay in appointing PEPFAR’s next leader.
* What’s Your Pleasure: The HIV prevention research pipeline, including a wide array of molecules and modalities (backed up by a smokin’ DJ), was the subject of this webinar, What's Your Pleasure? Expanding Your Choices on the HIV Prevention Buffet ([link removed]) . Access Code is required: iz5TqS2*

Best,
AVAC

============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])